Skip to content

Pandemics & Epidemics

A woman looks away while a healthcare professional gives her a COVID-19 vaccination
Home
Global Health Equity
Pandemics & Epidemics
ESG Policies & Positions

Johnson & Johnson is actively engaged in responding to and preventing a broad range of pandemic and epidemic threats; our experience in these areas has been built over more than a century. Our track record in advancing vaccines and novel treatment regimens and facilitating access to address multiple diseases such as HIV HIV Human immunodeficiency virus , TB TB Tuberculosis , COVID-19, Ebola, dengue and others, as well as addressing the growing threat of AMR AMR Antimicrobial resistance , has made a significant contribution to global public health and UN SDG SDG Sustainable Development Goal (of the United Nations) 3, which aspires to ensure healthy lives and promote well-being for all ages.

We maintain a wide range of collaborative partnerships to advance global health security and pandemic preparedness. One such collaboration, BLUE KNIGHT, is between JLABS JLABS Johnson & Johnson Innovation—JLABS and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, with the goal of accelerating the research and development of potential solutions for a range of diseases with pandemic potential. In 2021, the collaboration expanded residency opportunities to all JLABS and affiliate locations in North America as well as maintaining a virtual, global engagement model. By the end of 2021, the BLUE KNIGHT portfolio had grown to 19 companies globally, dedicated to anticipating potential health security threats, activating the global innovation community, and amplifying scientific and technological advancements.

Johnson & Johnson was a strategic sponsor of the 2021 World Health Summit to advance the collaboration, solidarity and commitment that will be necessary to tackle the infectious disease threats of both today and tomorrow. Four senior leaders representing our advances in Global Public Health shared their experience and insights at the conference. Learn more

A health worker meets with a family outside their home in Vietnam
Our Health for Humanity 2025 Goals
include a key focus on combating pandemics and epidemics, with three goals addressing pandemic preparedness, vaccination monitoring capabilities and access plans for endemic disease assets in our pipeline. In addition, we have specific goals relating to developing treatments and enhancing access to HIV and TB treatments.

Learn more

Health for Humanity 2025 Goals | Global Health Equity

Sustainability Goal Icons/Group 8041.png
Global Access Plans
Progress SVGs Symbols/On-Track-Symbol.svg
On track
Progress SVGs Symbols/On-Track-Symbol.svg
On track
Progress: Completed pipeline asset evaluation, internal assessments and developed a resource to support future global access plans.

Completed pilot of a relevant pipeline project.
Preventive Viral Vaccine Capabilities
Progress SVGs Symbols/On-Track-Symbol.svg
On track
Progress SVGs Symbols/On-Track-Symbol.svg
On track
Progress: Captured processes and learnings for future documentation in playbook.

The Johnson & Johnson COVID-19 vaccine was granted Emergency Use Authorization (EUA) from the U.S. FDA and Conditional Marketing Authorization by the European Commission, in addition to Emergency Use Listing (EUL) by the WHO. The Company’s COVID-19 vaccine was granted full approval by Health Canada.

Shipped 180 million doses of our COVID-19 vaccine to the African Union, COVAX and South Africa through advanced purchase agreements and country donations.
Vaccination Monitoring Platform
Progress SVGs Symbols/On-Track-Symbol.svg
On track
Progress SVGs Symbols/On-Track-Symbol.svg
On track
Progress: Completed first large use case of the Vaccination Monitoring Platform (VMP) through the UMURINZI campaign, fully vaccinating more than 200,000 individuals against Ebola in Rwanda.

Also deployed VMP via the WHO Solidarity trial for COVID-19 vaccines in three countries (Colombia, Mali and the Philippines).

Identified a partner to support implementation of the platform.

Previous Frontline Healthcare & Communities Next COVID-19
Back to Top